In the evolving landscape of cognitive health and dementia care, Pharmtrue stands at the forefront. We’re thrilled to introduce a groundbreaking product – Pharmtrue Memory Gummies. Consequently, this blog, rich in detail, explores the clinical rationale and research that underpin these transformative products.
The Genesis of Pharmtrue Memory Gummies
Understanding Dementia and Cognitive Decline
Dementia profoundly affects us during the aging process, leading to memory loss, cognitive decline, and behavioral changes. Traditionally, treatment often involves pharmaceuticals that may reduce life quality. Therefore, Pharmtrue embarked on a journey to find a solution that is both empathetic and effective.
The Role of Cannabinoids in Cognitive Health
Recent studies highlight the overall potential of cannabinoids in managing dementia symptoms. THC, CBD, and CBG have also shown promise in improving agitation, sleep disturbances, and cognitive functions in dementia patients.
The Development of Pharmtrue Memory Gummies
Stage 1 Gummies: “Memory Spark” & “Memory Soothe“
- Composition: “Memory Spark,” taken each morning and afternoon, contains 8 mg of CBD and 2 mg of THC. “Memory Soothe,” for the evening, comprises 5 mg CBG and 2.5 mg THC.
- Purpose: These gummies are emphatically crafted to gently introduce cannabinoids, providing subtle cognitive support and soothing effects.
Stage 2 Gummies: “Memory Ignite” & “Memory Calm“
- Composition: “Memory Ignite,” for morning and afternoon doses, has 5 mg of CBD and 5 mg of THC. The evening dose, “Memory Calm,” includes 10 mg CBG and 5 mg THC.
- Purpose: This stage offers a stronger blend for further advanced cognitive support, targeting more pronounced symptoms.
Scientific Backing and Rationale
The formulation of these memory supporting gummies is inspired by various clinical studies:
- Low and Moderate THC Doses: Research shows that THC doses from 2.5 mg to 25 mg effectively reduce dementia symptoms and are generally well-tolerated.
- Synergistic Effects of CBD and THC: Combining CBD with THC enhances therapeutic effects while reducing THC’s psychoactive impact.
- Inclusion of CBG: Recognized for its neuroprotective properties, CBG in the evening doses aims to specifically promote restful sleep in addition to support memory through cognitive rejuvenation.
Clinical Evidence Supporting Cannabis Use in Dementia Care
A wealth of studies, spanning from ancient times to today, have undeniably provided compelling evidence for using cannabis in treating dementia:
- Improved Behavioral Symptoms: Cannabis significantly reduces agitation, aggression, and wandering behaviors in dementia patients.
- Enhanced Cognitive Function: Some studies have observed improvements in cognitive abilities as well as daily living activities, a big support to overall memory function.
- Safety and Tolerability: Cannabis treatment demonstrates a high safety profile, with minimal adverse effects, even in older populations on multiple medications.
Usage and Recommendations
- Individualized Dosing: The two-stage approach provides guidelines, but individual responses may vary. Starting with Stage 1 Memory gummies and observing the effects before progressing to Stage 2 is recommended.
- Consultation with Healthcare Providers: Consulting healthcare professionals is crucial, especially for patients with pre-existing conditions or those on other medications.
Where to Get Pharmtrue Memory Gummies
Pharmtrue Memory Gummies are available at our downtown dispensary, additionally, our friendly and knowledgable staff can offer more information and guidance.
Conclusion: A Step Towards Compassionate Care
In conclusion, the launch of Pharmtrue Memory Gummies signifies a major milestone in our journey to blend modern science with natural healing. We are dedicated to further improving the lives of those affected by dementia, offering hope and new avenues for compassionate care.
- Bonini, S. A., et al. (2018). Cannabis sativa: A comprehensive ethnopharmacological review. Journal of Ethnopharmacology, 227, 300–315.
- Volicer, L., et al. (1997). Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. International Journal of Geriatric Psychiatry, 12(9), 913-919.
- Woodward, M. R., et al. (2014). Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients. The American Journal of Geriatric Psychiatry, 22(4), 415-419.
- Shelef, A., et al. (2016). Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia. Journal of Alzheimer’s Disease, 51(1), 15-19.
- Broers, B., et al. (2019). Prescription of a THC/CBD-based medication to patients with dementia: a pilot study in Geneva. Medical Cannabis and Cannabinoids, 2(1), 56-59.
- Herrmann, N., et al. (2019). Randomized placebo-controlled trial of nabilone for agitation in Alzheimer’s disease. The American Journal of Geriatric Psychiatry, 27(11), 1161-1173.
This blog is for educational purposes only and is not medical advice. Always consult with a healthcare professional before starting any new treatment.